Cancer specialist HiberCell snaps up analytics, computational tools in all-stock buyout; Praxis reveals new perimenopausal depression data
In a slightly unconventional deal, New York-based HiberCell is leveraging a chunk of its stock — still privately owned — to buy out Genuity Science and its suite of tools for genomics and multi-omic analytics, as well as an AI and machine learning platform.
The goal, according to CEO Alan Rigby, is to further HiberCell’s understanding of the adaptive stress phenotype and its role in cancer progression.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.